Evolus (NASDAQ:EOLS - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $82.18 million for the quarter.
Evolus Price Performance
NASDAQ EOLS traded down $0.12 during trading hours on Friday, reaching $9.53. 1,483,700 shares of the company's stock were exchanged, compared to its average volume of 815,094. The stock has a market cap of $614.49 million, a PE ratio of -10.71 and a beta of 0.97. Evolus has a one year low of $8.67 and a one year high of $17.82. The firm has a fifty day moving average of $9.53 and a 200-day moving average of $11.30. The company has a current ratio of 2.34, a quick ratio of 2.16 and a debt-to-equity ratio of 22.00.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on EOLS shares. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Finally, BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $23.75.
Get Our Latest Analysis on EOLS
Insider Buying and Selling
In other news, insider Rui Avelar sold 3,385 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the transaction, the insider owned 359,082 shares of the company's stock, valued at $3,544,139.34. This represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Sandra Beaver sold 6,494 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total value of $65,069.88. Following the completion of the transaction, the chief financial officer directly owned 167,089 shares in the company, valued at approximately $1,674,231.78. This trade represents a 3.74% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 153,571 shares of company stock worth $1,537,090. Company insiders own 5.90% of the company's stock.
Hedge Funds Weigh In On Evolus
Several hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company's stock worth $400,000 after acquiring an additional 1,838 shares during the last quarter. Millennium Management LLC increased its stake in Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after acquiring an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in shares of Evolus during the first quarter worth $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock worth $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Evolus by 484.8% during the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock valued at $841,000 after acquiring an additional 57,987 shares during the last quarter. Institutional investors own 90.69% of the company's stock.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access